The three peptides that dominate current GLP-1 receptor research — retatrutide, tirzepatide, and semaglutide — differ in receptor coverage, published trial depth, and structural complexity. This comparison summarises what the peer-reviewed literature reports as of 2026 for retatrutide research and for tirzepatide vs semaglutide research, and is intended for laboratory scientists sourcing material for in vitro and in vivo studies.
Research use only. This article summarises published trial and mechanism literature. Products are sold strictly for laboratory research and are not for human or animal consumption. No dosing or administration guidance is provided.
Receptor coverage at a glance
- Semaglutide — single-agonist. Binds the glucagon-like peptide-1 (GLP-1) receptor. This is the pharmacology that anchors the SUSTAIN and STEP clinical programs.
- Tirzepatide — dual-agonist. Binds both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The SURPASS and SURMOUNT programs form the primary evidence base.
- Retatrutide — triple-agonist. Binds GLP-1, GIP, and the glucagon receptor. Early- and mid-phase trials (published through 2023–2025) are the current retatrutide research foundation.
The therapeutic hypothesis behind multi-agonism is that GIP and glucagon signalling add complementary metabolic effects — improved insulin secretion, altered energy expenditure — on top of GLP-1's appetite and glycaemic effects.
Semaglutide research
Semaglutide is the most-published of the three. Landmark trials include SUSTAIN (type 2 diabetes) and STEP (weight management). Peer-reviewed follow-ups examine cardiovascular endpoints, hepatic outcomes, and long-term persistence of effect. Because the compound has been studied longest, the reproducibility base for in vitro comparators is deep. See our semaglutide research guide for a fuller breakdown.
Tirzepatide research
The SURPASS series compared tirzepatide against semaglutide and against insulin analogues in T2D populations; SURMOUNT examined weight endpoints. Head-to-head data (SURPASS-2) place tirzepatide's reported glycaemic and weight effects above semaglutide in the same trial arms. For a detailed dosing and reconstitution overview at the research level, see the tirzepatide research guide.
Retatrutide research
Retatrutide is the newest of the three in the public literature. The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 reported the largest weight-endpoint effect sizes of any GLP-1-family molecule to date; Phase 2 diabetes and MASLD data followed. As of 2026, Phase 3 programs (TRIUMPH) are ongoing and not yet fully reported. Reviewers note that the triple-agonist design is the mechanistic distinguisher, and that head-to-head Phase 3 data against tirzepatide are the most-awaited comparison.
Practical differences for research designers
| Peptide | Receptors | Published Phase 3 | Most-cited endpoint |
|---|---|---|---|
| Semaglutide | GLP-1 | Yes (SUSTAIN, STEP) | Weight, HbA1c, CV |
| Tirzepatide | GLP-1 + GIP | Yes (SURPASS, SURMOUNT) | Weight, HbA1c |
| Retatrutide | GLP-1 + GIP + GCG | Phase 2 complete; Phase 3 ongoing | Weight, hepatic fat |
For sourcing, note that all three are lyophilized peptides. Purity ≥ 98% by HPLC and batch-specific COAs are the norm — details in our peptide purity testing overview. Reconstituted material is temperature-sensitive: see research-peptide storage guidelines for the current best practice.
LabSpin research products
- Retatrutide GLP3-RT (10mg) — 10 vials · 15mg · 20mg · 30mg · 60mg
- Explore GLP-1 weight-loss peptides or the full peptide catalog. Regional availability is summarised at Where to buy research-grade GLP-1 peptides. Company background at the LabSpin homepage.
Summary
Retatrutide, tirzepatide, and semaglutide represent three generations of incretin-receptor pharmacology: single, dual, and triple agonism. The published trial base is deepest for semaglutide, strongest on cardiometabolic endpoints for tirzepatide, and most rapidly expanding for retatrutide. For laboratory studies, the choice of comparator should follow the receptor pharmacology being modelled and the availability of matched, purity-verified material.
Reminder: retatrutide, tirzepatide, and semaglutide are supplied for laboratory research use only. Not for human or animal consumption. No dosing, injection, or administration guidance is provided.